| Literature DB >> 31781082 |
Andrew Cameron1,2, Rahat Zaheer2, Tim A McAllister2.
Abstract
Horizontal gene transfer of integrative and conjugative elements (ICE) in bacterial pathogens of the bovine respiratory disease (BRD) complex has emerged as a significant cause of antimicrobial resistance (AMR) and therapeutic failure and mortalities in cattle. The aim of this study was to assess an AMR ICE occurring in Pasteurella multocida from a case of BRD, designated ICEMh1 PM22 for its structure and host genome insertion site, and to identify consequences for host fitness and antimicrobial therapy. The modular structure of ICEMh1-like elements found in several related livestock pathogens was compared to ICEMh1 PM22, and the repertoire of cargo genes in variable ICE modules was functionally categorized. AMR genes were identified as frequent additions to the variable modules of ICEMh1-like elements. Random PCR-based mapping of ICEMh1 PM22-genome junctions in transconjugants provided evidence that ICEMh1 PM22 integrates into the tRNA-leu for the UUG codon, and not into tRNA-leu for other codons. This was separately confirmed in the genomes of ICEMh1-like-harboring livestock pathogens. Bacterial genera harboring receptive tRNA-leuUUG were identified to establish the potential host range of ICEMh1-like elements. ICEMh1 PM22-carrying transconjugants in P. multocida and Mannheimia haemolytica were less fit than isogenic strains without the ICE when grown without antimicrobial selection. This fitness cost was abrogated in the presence of subinhibitory concentrations of antimicrobials. Despite this cost, ICEMh1 PM22 was retained in transconjugants in extended culture. To identify possible therapeutic efficiencies, antimicrobial combinations were screened for synergistic interactions against AMR ICEMh1 PM22-carrying transconjugants. No antimicrobial combination tested exhibited synergistic interactions against AMR P. multocida or M. haemolytica harboring ICEMh1 PM22. In conclusion, this study provided information on the structural variation of ICEMh1-like elements, refined the ICE insertion site and potential host range, and demonstrated the risk and consequences for AMR following horizontal transfer of ICE into BRD pathogens.Entities:
Keywords: Mannheimia haemolytica; Pasteurella multocida; antimicrobial resistance; bovine respiratory disease; cattle; conjugative transposon; integrative and conjugative element; synergy
Year: 2019 PMID: 31781082 PMCID: PMC6861422 DOI: 10.3389/fmicb.2019.02608
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Genomic characterization of the ICEMh1-like variant ICEMh1PM22. (A) Gene schematic of ICEMh1PM22 with genes shown as arrows and colored by functional characteristics, as shown in panel (C). (B) Comparison of ICEMh1PM22 with selected Pasteurellaceae genomic ICE sequences. In some cases, the ICE region cannot be delimited by the identification of the flanking direct repeat and includes sequences likely external to the ICE. Histograms represent the frequency and sequence identity (color) of alignments to ICEMh1PM22: red, >95% sequence identity; orange, >95%; green, <80%; blue, <60%. (C) Frequencies of annotated genes by functional characteristics found in conserved (left) and variable (right) regions in 41 ICEMh1-like-containing Pasteurellaceae (with >80% sequence identity and >50% query coverage alignment to ICEMh1PM22).
FIGURE 2Identification of tRNA-leuUUG as the putative attB insertion site of ICEMh1-like elements and predicted host range. (A) Schematic for ICE orientation and random PCR mapping of ICEMh1PM22 junctions in 18 Mannheimia haemolytica and 18 Pasteurella multocida transconjugants. ICEMh1PM22 insertions in every transconjugant were identical and aligned to a specific tRNA-leu in the genomes of P. multocida strain 36950 and M. haemolytica M42548. (B) Sequence logo of left and right MUSCLE-aligned junctions identified in 41 Pasteurellaceae harboring ICEMh1-like sequences. The left and right ends of ICEMh1-like variants contain a conserved direct repeat (DR; 5′-GATTCAAAATC-3′) attL conserves the tRNA TψC loop’s imperfect palindrome (5′-CGGTTCGAGTCCG-3′). The attL and attR sites are designated with respect to ICEPmu1 in Michael et al. (2011b). (C) Neighbor-joining tree of all tRNA-leu from 41 Pasteurellaceae harboring ICEMh1-like sequences. All ICEMh1-like insertions were associated with tRNA-leuUUG. (D) Predicted structure of tRNA-leuUUG showing presumptive ICEMh1 attB attachment site (also encoding the tRNA anticodon) and palindrome. (E) Frequencies of tRNA-leu codon types in 41 Pasteurellaceae harboring ICEMh1-like sequences. (F) Predicted host range of ICEMh1-like elements based on tRNA-leuUUG alignment by BLAST and strict (100% identity) conservation of direct repeat and palindrome. Colors are arbitrary.
FIGURE 3ICEMh1PM22 fitness costs, addiction, and consequences for antimicrobial resistance in transconjugants. (A) Growth curves of P. multocida CCUG 17976 (spontaneous rifampin-resistant mutant) and isogenic ICEMh1PM22 transconjugant. Mean of 4 biological replicates with SEM. (B) Growth curves of M. haemolytica ATCC 33396 (spontaneous rifampin-resistant mutant) and isogenic ICEMh1PM22 transconjugant. Mean of 4 biological replicates with SEM. (C) Luciferase-based competition index from co-cultures of ICEMh1PM22 transconjugants and E. coli DH5α harboring the luciferase expression plasmid pAKlux2. Mean of 4 biological replicates with SEM; t-test, ∗P ≤ 0.05. (D) Long-term repeated passage of ICEMh1PM22 transconjugants. Transconjugants were grown in MH (no drug) or MH + 0.5 MIC (subinhibitory; MIC for susceptible P. multocida CCUG 17976 or M. haemolytica ATCC 33396 WT) for 150 days and plated on media with or without selective concentrations of indicated antimicrobials (i.e., 0.5 MIC for non-susceptible isogenic transconjugants). Mean of 3 biological replicates with SEM. (E) Upper panel: growth curves of co-cultures of E. coli DH5α pAKlux2 and E. coli DH5α, P. multocida CCUG 17976 ICEMh1PM22, or M. haemolytica ATCC 33396 ICEMh1PM22 in subinhibitory (0.5 MIC for susceptible P. multocida CCUG 17976 or M. haemolytica ATCC 33396) concentrations of oxytetracycline (left) or spectinomycin (right). Mean of 3 biological replicates with SEM. Lower panel: detection of E. coli luciferase production in co-cultures (as above) with either oxytetracycline (left) or spectinomycin (right). (F) Schematic of checkerboard synergy assay for drug interaction screening.
MIC changes in transconjugants.
| Oxytetracycline | 0.250 | 16 | 0.125 | 16 |
| Chlortetracycline | 0.125 | 2 | 0.125 | 1 |
| Tylosin | 32 | 256 | 32 | 256 |
| Tilmicosin | 4 | 64 | 2 | 64 |
| Gamithromycin | 2 | 64 | 1 | 64 |
| Aminoglycosides | ||||
| Spectinomycin | 64 | 1024 | 64 | 1024 |
| Neomycin | 16 | 256 | 4 | 256 |
| Penicillin G | 0.125 | 0.125 | 0.125 | 0.125 |
| Ampicillin | 0.250 | 0.250 | 0.125 | 0.125 |
| Ceftiofur | 0.125 | 0.125 | 0.125 | 0.125 |
| Sulfamethazine | 128 | 1024 | 128 | 1024 |
| Sulfamethoxazole | 128 | 512 | 128 | 1024 |
| Enrofloxacin | 0.250 | 0.250 | 0.250 | 0.250 |
| Tiamulin | 8 | 8 | 4 | 8 |
| Clindamycin | 2 | 1024 | 4 | 1024 |
| Florfenicol | 1 | 1 | 1 | 1 |
Results of checkerboard synergy testing (FICIs) with non-susceptible antimicrobial combinations.
| Oxytetracycline | 1–64 | 16 | 0.84 ± 0.23 (0.63) | 0.57 ± 0.24 (0.31) | 0.98 ± 0.22 (0.63) | 0.99 ± 0.17 (0.75) | No interactions |
| Spectinomycin | 64–4096 | 1024 | 0.51 ± 0.30 (0.25) | 0.76 ± 0.63 (0.31) | 0.74 ± 0.65 (0.28) | No interactions | |
| Tilmicosin | 4–256 | 32 | 0.60 ± 0.28 (0.38) | 0.54 ± 0.09 (0.38) | No interactions | ||
| Tylosin | 16–1024 | 256 | 0.63 ± 0.09 (0.53) | No interactions | |||
| Sulfamethazine | 32–2048 | 1024 | No interactions | ||||
| Oxytetracycline | 1–64 | 16 | 1.23 ± 0.18 (1.06) | 0.58 ± 0.05 (0.50) | 6.59 ± 5.82 (2.00) | 1.21 ± 0.18 (1.03) | No interactions |
| Spectinomycin | 64–4096 | 1024 | 0.60 ± 0.28 (0.38) | 0.59 ± 0.28 (0.38) | 1.11 ± 0.09 (1.00) | No interactions | |
| Tilmicosin | 4–256 | 32 | 0.58 ± 0.28 (0.38) | 0.93 ± 0.25 (0.56) | No interactions | ||
| Tylosin | 16–1024 | 256 | 0.84 ± 0.23 (0.56) | No interactions | |||
| Sulfamethazine | 32–2048 | 1024 | No interactions | ||||
Results of checkerboard synergy testing (FICIs) with non-susceptible and susceptible antimicrobial combinations.
| Penicillin G | 0.0078–0.5 | 0.125 | 1.11 ± 0.09 (1.00) | 0.59 ± 0.25 (0.25) | 0.65 ± 0.09 (0.56) | No interactions |
| Enrofloxacin | 0.0078–0.5 | 0.250 | 0.64 ± 0.30 (0.31) | 0.70 ± 0.29 (0.38) | 0.57 ± 0.23 (0.31) | No interactions |
| Florfenicol | 0.0625–4 | 1 | 0.68 ± 0.22 (0.50) | 0.61 ± 0.24 (0.38) | 0.81 ± 0.23 (0.56) | No interactions |
| Ceftiofur | 0.0313–2 | 0.125 | 1.28 ± 0.18 (1.06) | 1.28 ± 0.18 (1.06) | 3.29 ± 1.23 (1.50) | No interactions |
| Chlortetracycline | 0.0625–4 | 1 | 1.21 ± 0.18 (1.03) | 1.05 ± 0.51 (0.56) | 0.57 ± 0.24 (0.31) | No interactions |
| Penicillin G | 0.0078–0.5 | 0.125 | 0.93 ± 0.25 (0.56) | 0.65 ± 0.09 (0.56) | 1.13 ± 0.10 (1.00) | No interactions |
| Enrofloxacin | 0.0078–0.5 | 0.250 | 1.23 ± 0.18 (1.06) | 0.98 ± 0.22 (0.63) | 0.99 ± 0.20 (0.63) | No interactions |
| Florfenicol | 0.0625–4 | 1 | 0.74 ± 0.25 (0.50) | 0.53 ± 0.09 (0.56) | 0.61 ± 0.24 (0.38) | No interactions |
| Ceftiofur | 0.0313–2 | 0.125 | 1.14 ± 0.11 (1.00) | 1.28 ± 0.18 (1.06) | 1.14 ± 0.11 (1.00) | No interactions |
| Chlortetracycline | 0.0625–4 | 1 | 1.13 ± 0.10 (1.00) | 1.13 ± 0.10 (1.00) | 0.61 ± 0.24 (0.38) | No interactions |